Molecular Partners【0QXX】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

25.20

買値

0.00

売値

0.00

出来高

6,450

0.00 日の範囲 0.00

25.20 52 週間の範囲 25.20

時価総額

916.121M

前日終値

25.20

始値

時刻

3.85

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

237

発行済株式数

36,354,000

配当利回り

PER

-2.48

1 株当たり利益 (EPS)

-1.71

歳入

7.04M

純利益

-61.98M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.molecularpartners.com

本社

Schlieren, Che

設立

Molecular Partners Ag is listed in the Pharmaceutical Preparations sector of the ロンドン証券取引所 with ticker 0QXX. The last closing price for Molecular Partners was CHF25.20. Over the last year, Molecular Partners shares have traded in a share price range of CHF 25.20 to CHF 25.20.

Molecular Partners currently has 36,354,000 shares in issue. The market capitalisation of Molecular Partners is CHF916.12 million. Molecular Partners has a price to earnings ratio (PE ratio) of -2.48.

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024 DLL3 targeting Radio-DARPin MP0712 to enter...

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call Participation in fireside...

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer New agreement enables both companies to...

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare...

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January ZURICH-SCHLIEREN...

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH...

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024...

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition Clinical update from ongoing MP0533 phase...

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical...

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners Announces Pricing of $20 Million Underwritten Offering ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE...

期間 †	始値	高値	安値	平均出来高	VWAP
1	25.2	25.2	25.2	420	25.2	DE
4	25.2	25.2	25.2	122	25.2	DE
12	25.2	25.2	25.2	237	25.2	DE
26	25.2	25.2	25.2	376	25.2	DE
52	25.2	25.2	25.2	364	25.2	DE
156	25.2	25.2	25.2	5771	25.2	DE
260	25.2	25.2	25.2	5170	25.2	DE

0QXX - Frequently Asked Questions (FAQ)

What is the current Molecular Partners share price?

The current share price of Molecular Partners is CHF 25.20

How many Molecular Partners shares are in issue?

Molecular Partners has 36,354,000 shares in issue

What is the market cap of Molecular Partners?

The market capitalisation of Molecular Partners is CHF 916.12M

What is the 1 year trading range for Molecular Partners share price?

Molecular Partners has traded in the range of CHF 25.20 to CHF 25.20 during the past year

What is the PE ratio of Molecular Partners?

The price to earnings ratio of Molecular Partners is -2.48

What is the cash to sales ratio of Molecular Partners?

The cash to sales ratio of Molecular Partners is 21.8

What is the reporting currency for Molecular Partners?

Molecular Partners reports financial results in CHF

What is the latest annual turnover for Molecular Partners?

The latest annual turnover of Molecular Partners is CHF 7.04M

What is the latest annual profit for Molecular Partners?

The latest annual profit of Molecular Partners is CHF -61.98M

What is the registered address of Molecular Partners?

The registered address for Molecular Partners is WAGISTRASSE 14, SCHLIEREN, 8952

What is the Molecular Partners website address?

The website address for Molecular Partners is www.molecularpartners.com

Which industry sector does Molecular Partners operate in?

Molecular Partners operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
ROQRoquefort Therapeutics Plc	2.30p (48.39%)	33.61M
GCMGcm Resources Plc	1.825p (30.36%)	8.01M
CORACora Gold Limited	3.95p (27.42%)	2.15M
EMHEuropean Metals Holdings Limited	8.25p (26.92%)	1.07M
ATMAndrada Mining Limited	3.375p (21.62%)	121.54M
CAPDCapital Limited	60.60p (-21.30%)	3.66M
CKNClarkson Plc	3,510.00p (-20.41%)	465.72k
BIOMBiome Technologies Plc	1.00p (-20.00%)	703.46k
ZOOZoo Digital Group Plc	10.875p (-17.92%)	13.45M
CTAICatenai Plc	0.21p (-17.65%)	13.8M
VELAVela Technologies Plc	0.0028p (0.00%)	1.35B
PREMPremier African Minerals Limited	0.01225p (-5.04%)	461.14M
ORCPOracle Power Plc	0.0165p (0.00%)	382.37M
LLOYLloyds Banking Group Plc	69.38p (-2.17%)	355.11M
SYMESupply@me Capital Plc	0.0037p (0.00%)	217.78M

TightCoil 5分前

The Federal National Mortgage Association, commonly known as Fannie Mae, is a United States government-sponsored enterprise and, since 1968, a publicly traded company. Founded in 1938 during the Great Depression as part of the New Deal, the corporation's purpose is to expand the secondary mortgage m

FNMA

asiqlimited 5分前

Apologies for the delay in updating on the current status. There has been a holdup with a major share/convertible note holder in finalising the return of the share certificates which are being cancelled as part if extinguishing the note and settling the debt.
We have received all signed docum

IPTK

jhdf51 5分前

Yeah, I don’t trust anything “…he’ll this could run down to $50, $60…they give the escrows their due and then buy us out at a low price then run it over $200.

JHD

COOP

janice shell 7分前

I am puzzled. Why is Bolshie so interested in cat videos?

spdpro 8分前

i'll be looking closer to "it" when clear of my svix play

price_and_volume 9分前

I appreciate the response.
When did I say the market is wrong in that post? You didn't - I was simply asking the question. I believe there are at least 4 companies that will have a major part in HMBL. Maybe 5. We will likely know if I am right within 21 days. Thx again - I think many are loo

HMBL

TightCoil 10分前

Google Fannie and Freddie Factoids
The Federal National Mortgage Association, commonly known as Fannie Mae, is a United States government-sponsored enterprise and, since 1968, a publicly traded company. Founded in 1938 during the Great Depression as part of the New Deal, the corporation's pur

FNMA

955 14分前

Globalists exercising PUT OPTIONS in March to collapse Wall Street while placing blame on Trump Policies
Beware of all the FAKE NEWS being propagated. Don't take the bait!

https://investorshub.advfn.com/uimage/uploads/2025/3/11/yjqbzCrashingEconomy.jpg

https://i

MC10459 17分前

More sells than buys. A lot of .0003s dropped. Volume declining with the price. .0001 might be around the corner.

HMBL

janice shell 18分前

I agree...

lambchops 19分前

You hopping back in, K? OKLO must hold support or the next support is in the 19's.

LC

OKLO

OKLO

janice shell 19分前

https://www.news9.com/story/67cf894371c2b85f2c70ae9b/ok-supreme-court-freezes-bible-buying-plan-osde

ombowstring 20分前

All things are working out according to God's purposes. There is a reason for everything.

Ecclesiastes 3:1 To every thing there is a season, and a time to every purpose under the heaven:

2 A time to be born, and a time to die; a time to plant, and a time to pluck up th

lodas 20分前

Treatment of class 19....... notice the part that says JPM is the sole and LEGAL OWNER OF THE TPS......this text is from the amended POR 7....please read....... Lodas

20.
Preferred Equity Interests (Class 19)

Pursuant to the Seventh Amended Plan, the Preferred

JPM

Lime Time 20分前

I'm locked n loaded at .0001

I can't wait to crush this guy

VGTL

SSKILLZ1 21分前

I agree on division problem because I like the red sox, but the o's are not better than last year, they don't have an ace. They lost santander who hit 44 homeruns for them. O's could still compete for a wc, but there just isn't alot in the AL even without cole the yanks will easily make the playoffs

jhdf51 21分前

Be humble …don’t laugh… it could turn out not like you imagine… and humble pie is a disgusting taste.

Sincerely,

JHD

COOP

zerk_zerk 21分前

Where did I say that Pulte's confirmation was on 3/11? I specifically said in my earlier post that it wouldn't be on 3/11.

And the post you replied to was merely stating that next week the Senate is not in session and hoping that Pulte gets confirmed before then.

How

FNMA

lambchops 22分前

oo-La-La! Little frenchy Lamb chops sez SIPC is up 37%. Biggity-big Panzer boomage!!! Something goody-good about to happen???? Bring the Panzer division to the front lines, Herr Pansy!

LC

SIPC

SIPC

The_Gman 23分前

🤔 didn’t have that on my bingo card.

KILLAZILLA 23分前

LOLOLOLOL....REPEATING LIES FROM THESE GRIFTERS BY A KNOWN SHILL WITH ABSOLUTELY ZERO CREDIBILITY!!!

THAT CERTAINLY DOESN'T HELP THIS POS SCAM!!!!

"Puzzle pieces"=PUMPER GARBAGE!!!

XERI

littlejohn 24分前

ok, let me xplain it, big-short pumped tsla

way up in the winter,

and then can load short positions up...

big shorts get other things pumped up

with Stargate pump not long ago...

and big shorts load more short positions...

bigbux1 25分前

NYBob, you got the symbol for that high grade mine? It says HMXZF but that's not right.

HGLD

KILLAZILLA 25分前

Link? I searched and went to wdlf. "Kenneth T." is set to private.

WDLF

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Molecular Partners Ag (0QXX)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Molecular Partners Ag について

0QXX 最新ニュース

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

0QXX - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Molecular Partners Ag (0QXX) 銘柄情報

Molecular Partners Ag (0QXX)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Molecular Partners Ag について

0QXX 最新ニュース

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

0QXX - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する